The discovery of NLRC5 as the key transcriptional activator of MHC-I and APM genes that undergoes similar genetic and epigenetic repression in cancers has raised the possibility of using NLRC5 directly to restore MHC-I expression without causing undesirable side effects [58]. Here, ANPEP is linked to cancer.